ANDROGENS, ESTROGENS AND PROGESTERONE IN PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA, RELATION WITH GROWTH AND TRANCRIPTION FACTORS
- Authors: Kovaleva I.V1, Spirina L.V1,2
-
Affiliations:
- Siberian State Medical University
- Cancer Research Institute, Tomsk NMRC of the RAS
- Issue: Vol 15, No 3S (2020)
- Pages: 94-95
- Section: Articles
- Submitted: 17.01.2023
- Published: 15.12.2020
- URL: https://genescells.ru/2313-1829/article/view/122829
- DOI: https://doi.org/10.23868/gc122829
- ID: 122829
Cite item
Abstract
Full Text
About the authors
I. V Kovaleva
Siberian State Medical University
Email: irina.kovalyova.kovaleva@mail.ru
Tomsk, Russia
L. V Spirina
Siberian State Medical University; Cancer Research Institute, Tomsk NMRC of the RASTomsk, Russia
References
- Schatten H. Brief Overview of Prostate Cancer Statistics, Grading, Diagnosis and Treatment Strategies. Adv Exp Med Biol. 2018; 1095:1-14.
- Feng Q., He B. Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer. Front Oncol. 2019; 9: 858.
- Chen R., Yu Y., Dong X. Progesterone receptor in the prostate: A potential suppressor for benign prostate hyperplasia and prostate cancer. J Steroid Biochem Mol Biol. 2017; 166: 91-96. А.А. Коваленко, М.В. Захарова, А.П. Шварц,